Drug Profile
Pneumococcal vaccine recombinant - GlaxoSmithKline
Alternative Names: 2189242A; GSK 2189242A; S. pneumoniae adult vaccine - GlaxoSmithKlineLatest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Otitis media; Pneumococcal infections
Most Recent Events
- 10 Jul 2019 No development reported - Phase-II for Otitis media (Combination therapy, In infants, Prevention) in USA (IM)
- 10 Jul 2019 No development reported - Phase-II for Pneumococcal infections (Combination therapy, In infants, Prevention) in USA (IM)
- 10 Jul 2019 No development reported - Phase-II for Pneumococcal infections (In children, In infants, Prevention) in Gambia (IM)